| Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers PC Fong, DS Boss, TA Yap, A Tutt, P Wu, M Mergui-Roelvink, P Mortimer, ... New England Journal of Medicine 361 (2), 123-134, 2009 | 4429 | 2009 |
| Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition N McCabe, NC Turner, CJ Lord, K Kluzek, A Białkowska, S Swift, ... Cancer research 66 (16), 8109-8115, 2006 | 1517 | 2006 |
| Targeting the DNA damage response in cancer MJ O’Connor Molecular cell 60 (4), 547-560, 2015 | 1515 | 2015 |
| High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs S Rottenberg, JE Jaspers, A Kersbergen, E van der Burg, AOH Nygren, ... Proceedings of the National Academy of Sciences 105 (44), 17079-17084, 2008 | 1149 | 2008 |
| Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action Y Pommier, MJ O’Connor, J De Bono Science translational medicine 8 (362), 362ps17-362ps17, 2016 | 720 | 2016 |
| 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1 KA Menear, C Adcock, R Boulter, X Cockcroft, L Copsey, A Cranston, ... Journal of medicinal chemistry 51 (20), 6581-6591, 2008 | 665 | 2008 |
| Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors JE Jaspers, A Kersbergen, U Boon, W Sol, L Van Deemter, SA Zander, ... Cancer discovery 3 (1), 68-81, 2013 | 558 | 2013 |
| The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300 H Zimmermann, R Degenkolbe, HU Bernard, MJ O’Connor Journal of virology 73 (8), 6209-6219, 1999 | 458 | 1999 |
| Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion SE Golding, E Rosenberg, N Valerie, I Hussaini, M Frigerio, XF Cockcroft, ... Molecular cancer therapeutics 8 (10), 2894-2902, 2009 | 417 | 2009 |
| Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin B Evers, R Drost, E Schut, M de Bruin, E van der Burg, PWB Derksen, ... Clinical Cancer Research 14 (12), 3916-3925, 2008 | 405 | 2008 |
| Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells H Dev, TWW Chiang, C Lescale, I de Krijger, AG Martin, D Pilger, ... Nature cell biology 20 (8), 954-965, 2018 | 402 | 2018 |
| hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage A Moumen, P Masterson, MJ O'Connor, SP Jackson Cell 123 (6), 1065-1078, 2005 | 397 | 2005 |
| RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, ... Annals of Oncology 29 (5), 1203-1210, 2018 | 383 | 2018 |
| Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition PM Krawczyk, B Eppink, J Essers, J Stap, H Rodermond, H Odijk, ... Proceedings of the National Academy of Sciences 108 (24), 9851-9856, 2011 | 380 | 2011 |
| PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers PG Pilié, CM Gay, LA Byers, MJ O'Connor, TA Yap Clinical Cancer Research 25 (13), 3759-3771, 2019 | 324 | 2019 |
| The overexpression of specialized DNA polymerases in cancer MR Albertella, A Lau, MJ O’Connor DNA repair 4 (5), 583-593, 2005 | 312 | 2005 |
| A role for polymerase η in the cellular tolerance to cisplatin-induced damage MR Albertella, CM Green, AR Lehmann, MJ O'Connor Cancer research 65 (21), 9799-9806, 2005 | 292 | 2005 |
| AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity JHL Fok, A Ramos-Montoya, M Vazquez-Chantada, PWG Wijnhoven, ... Nature communications 10 (1), 5065, 2019 | 275 | 2019 |
| BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency C Sun, J Yin, Y Fang, J Chen, KJ Jeong, X Chen, CP Vellano, Z Ju, ... Cancer cell 33 (3), 401-416. e8, 2018 | 275 | 2018 |
| Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients … YJ Bang, SA Im, KW Lee, JY Cho, EK Song, KH Lee, YH Kim, JO Park, ... Journal of clinical oncology 33 (33), 3858-3865, 2015 | 274 | 2015 |
